The US Food and Drug Administration (FDA) has expanded indication for the noninvasive BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMSTM) System to include treatment of comorbid anxiety symptoms in adult patients with depression, the company has announced. As reported by Medscape Medical News, the neurostimulation system has previously received FDA approval for treatment-resistant major depression,